Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 24;29(1):27. doi: 10.3892/ol.2024.14773

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2024 Qin et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Therapy timeline of the patient. CT images of the patient in (A) January, 2021, (B) March, 2021, (C) May, 2021, (D) July, 2021, (E) February, 2022, (F) March, 2022, (G) May, 2022, (H and I) October, 2022. (J) CT findings before treatment with cadonilimab + anlotinib in November 2022. CT findings after 3 and 5 cycles of treatment with cadonilimab + anlotinib in (K) January 2023, (L) March 2023, respectively. The new lesion of retroperitoneal lymph node metastases is indicated by a yellow arrows, and red arrows indicate the changes in primary tumor and lymph node metastases before and after treatment with cadonilimab + anlotinib. BOR, best of response; PR, partial response; SD, stable disease; PD, progressive disease; EP, etoposide + cisplatin.